Lawmakers contemplate the return of mental health institutions in response to the drug crisis; new measures to rein in insulin prices take effect; FDA intensifies efforts to curb the teen vaping epidemic.
Congress is deliberating the revival of mental hospitals as a response to the escalating drug crisis, according to Politico. The proposal, while aiming to provide comprehensive care for individuals struggling with substance use disorders and mental health issues, has generated significant controversy. Supporters argue for a holistic approach, while critics express concerns about potential stigmatization and the need for more nuanced solutions in addressing the complex intersection of mental health and drug addiction.
In response to growing concerns over rising insulin prices, major insulin manufacturers, including Sanofi, Novo Nordisk, and Eli Lilly, have initiated measures added price caps and have made substantial reductions in list prices, which took effect on January 1, according to CNN. Sanofi has instituted a $35 monthly cap on out-of-pocket costs for its most widely prescribed insulin in the United States, following Novo Nordisk and Eli Lilly, which placed insulin caps on their products in 2023. The moves should make insulin more affordable for the 8.4 million Americans dependent on the life-saving medication, coming in response to mounting public pressure, changes in Medicaid rebate programs, and the entry of new competitors.
The FDA's recent crackdown on the importation of Elf Bar, a widely popular e-cigarette brand, is indicative of an escalated campaign against teen vaping, although thousands of other flavored e-cigarettes continue to make their way into the nation, according to The Associated Press. As health authorities grapple with the rising rates of youth nicotine addiction, the efforts to seize shipments of e-cigarettes are both applauded for their potential impact on public health and criticized for potential unintended consequences. The move underscores the ongoing challenge of balancing access for adult smokers seeking harm reduction with the imperative to protect younger generations from the dangers of nicotine addiction.
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Frameworks for Advancing Health Equity: Pharmacy Support for Non-Hodgkin Lymphoma
December 19th 2024Rachael Drake, pharmacy technician coordinator, University of Kansas Health System, explains how her team collaborates with insurance companies and providers to support treatment access for patients with non-Hodgkin lymphoma.
Listen
ICYMI: Highlights From AMCP Nexus 2024
December 26th 2024Check out this year's top coverage from The Academy of Managed Care Pharmacy (AMCP) Nexus 2024 meeting, which included relevant topics in health care policy, novel pharmaceutical developments, financial considerations across multiple conditions, and more.
Read More